Search clinical trials for: Tyrosine Kinase Inhibitor gefitinib (Iressa)

Total 8020 results

AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
Tan Tock Seng Hospital
AstraZeneca; Singapore Cancer Syndicate.

Unknown

Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma

Liver Cancer

Singapore
Dana-Farber Cancer Institute
AstraZeneca

Active, not recruiting

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer

United States
Lady Davis Institute
Jewish General Hospital

Unknown

A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC (CURCUMIN)

Lung Cancer

Canada
University Health Network, Toronto
AstraZeneca

Completed

Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC

LUNG CANCER

Canada
Tianjin Medical University Cancer Institute and...

Suspended

Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
AstraZeneca

Terminated

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Non Small Cell Lung Carcinoma

Italy
Sun Yat-sen University
Wu Jieping Medical Foundation

Completed

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

Non-small Cell Lung Cancer

China
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
AstraZeneca

Terminated

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

Brain Neoplasms | Non Small Cell Lung Cancer

Italy
Guangdong Provincial People's Hospital

Unknown

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastasis
AstraZeneca

Completed

Iressa Expanded Access Program (EAP)

Carcinoma | Neoplasm | Non-small-cell Lung | Metastases

United States
AstraZeneca

Completed

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment (ICARUS)

Lung Cancer

Italy
Chonnam National University Hospital
AstraZeneca

Completed

Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC) (ReGaiN)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
AstraZeneca

Completed

IRESSA™ (Gefitinib) in Breast Cancer Patients

Breast Cancer
AstraZeneca

Completed

Open-Label Extension of Other SZ1839 (Iressa) Trials

Cancer
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IIIB Non-small Cell Lung Cancer | Anaplastic Thyroid Cancer | Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous... and other conditions

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); AstraZeneca

Terminated

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Lung Cancer

United States
AstraZeneca

Withdrawn

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Carcinoma, Squamous Cell

Italy
Dana-Farber Cancer Institute
Boston Children's Hospital; Brigham and Women's Hospital

Completed

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Myelogenous Leukemia, Acute

United States
Massachusetts General Hospital

Completed

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Terminated

Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (ARPEGE)

Brain Metastasis | EGFR-mutated Lung Adenocarcinoma

France
University of Chicago
National Cancer Institute (NCI)

Completed

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Head and Neck Cancer

United States
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
Hunan Kelun Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions

Bioequivalence Study
Fujian Cancer Hospital

Unknown

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (Geber)

Lung Adenocarcinoma | EGFR Mutation

China
Hunan Kelun Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Gefitinib Tablets Under Fed Conditions

Healthy
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Bronchoalveolar Cell Lung Cancer

United States
Groupe Oncologie Radiotherapie Tete et Cou
AstraZeneca

Terminated

Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas

Head and Neck Cancer

France
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Malignant Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma

United States
National Cancer Centre, Singapore

Completed

PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery (PROGRESS)

Non-small Cell Lung Cancer

Singapore
Peking University Cancer Hospital & Institute

Unknown

Blood Detection of EGFR Mutation For Iressa Treatment (Benefit)

Lung Adenocarcinoma

China
Kanazawa University

Unknown

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer (VICTORY-J)

Non-Small-Cell Lung Carcinoma

Japan
ZhuGuangYing
Zhejiang Cancer Hospital; 307 Hospital of PLA; Fudan University; Cancer Institute... and other collaborators

Unknown

Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Completed

Third-line Treatment of Gefitinib in NSCLC Patients

Non Small Cell Lung Cancer

China
Seoul Veterans Hospital

Unknown

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy (SIIS)

Squamous Cell Carcinoma of Bronchus

Korea, Republic of
AstraZeneca

Completed

Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

Locally Advanced Prostate Cancer

Norway
Telik

Completed

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

United States, Australia, Brazil, Chile, Germany, Argentina, Italy, United Kingdom
St. Jude Children's Research Hospital
AstraZeneca

Completed

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors

Glioblastoma | Osteosarcoma | Neuroblastoma | Rhabdomyosarcomas

United States
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
AstraZeneca

Completed

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) (INFORM)

Non-small Cell Lung Cancer (NSCLC)

China
Samsung Medical Center

Unknown

Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Pulmonary Cancer

Korea, Republic of
Jiangmen Central Hospital

Unknown

The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer

Breast Cancer
University of Chicago

Completed

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Head and Neck Cancer

United States
University of Chicago
AstraZeneca

Completed

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Head and Neck Neoplasms

United States
Asan Medical Center
AstraZeneca

Unknown

First Line Gefitinib by FDG-PET Metabolic Response

Non-small Cell Lung Cancer

Korea, Republic of

Search clinical trials for: Tyrosine Kinase Inhibitor gefitinib (Iressa)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations